MannKind's inhaled diabetes treatment wins FDA panel support

04/2/2014 | Reuters

An FDA advisory panel endorsed the approval of MannKind's inhaled insulin therapy Afrezza as a treatment for type 1 and type 2 diabetes. Afrezza could especially benefit type 2 diabetes patients who have difficulty injecting themselves with insulin because of poor eyesight or hand arthritis, as well as patients with extreme fear of needles, the panel said. A final decision is expected by April 15.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT